MARKET

TCRT

TCRT

Alaunos Therapeutics, Inc
NASDAQ
0.1345
-0.0157
-10.45%
After Hours: 0.1326 -0.0019 -1.41% 19:53 09/20 EDT
OPEN
0.1479
PREV CLOSE
0.1502
HIGH
0.1500
LOW
0.1312
VOLUME
1.81M
TURNOVER
0
52 WEEK HIGH
2.800
52 WEEK LOW
0.1111
MARKET CAP
32.36M
P/E (TTM)
-0.8375
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TCRT last week (0911-0915)?
Weekly Report · 3d ago
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 09/14 16:58
Weekly Report: what happened at TCRT last week (0904-0908)?
Weekly Report · 09/11 12:03
Alaunos Therapeutics, Inc: Statement of changes in beneficial ownership of securities
Press release · 09/05 22:11
Weekly Report: what happened at TCRT last week (0828-0901)?
Weekly Report · 09/05 08:48
Alaunos Therapeutics, Inc: Report of proposed sale of securities
Press release · 09/01 17:02
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
NASDAQ · 08/28 14:45
Weekly Report: what happened at TCRT last week (0821-0825)?
Weekly Report · 08/28 12:11
More
About TCRT
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Webull offers kinds of Alaunos Therapeutics Inc stock information, including NASDAQ:TCRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCRT stock methods without spending real money on the virtual paper trading platform.